Social Anxiety Disorder Clinical Trial
Official title:
D-cycloserine Enhancement of Exposure in Social Phobia
This study will assess the effectiveness of D-cycloserine combined with cognitive-behavior therapy in treating people with social anxiety disorder.
Social anxiety disorder (SAD) is among the most common psychiatric conditions and is
associated with significant distress and dysfunction in social situations. Although treatment
with cognitive-behavior therapy (CBT) is known to help remedy SAD, many patients do not
respond to this treatment and most do not reach full recovery. In CBT, patients undergo
repeated and prolonged exposure practices to feared social situations to learn better ways to
deal with anxiety in these settings. Exposure therapy is based on animal models of extinction
of conditioned fears, and recent animal research has identified some of the core pathways and
neurotransmitters involved in fear extinction. D-cycloserine (DCS) is a drug that appears to
facilitate learning and the process of extinction of conditioned fear in both animals and
humans. This study will assess the effectiveness of DCS combined with CBT in treating people
with SAD.
Participants in this double-blind study will be randomly assigned to an active or control
group. All participants will attend 18 study visits at the Center for Anxiety and Related
Disorders over a 9-month period. There will be 12 CBT sessions of 90 minutes each and 6
assessment visits. The CBT sessions will help participants to become more comfortable with
social situations. During 5 of the CBT sessions, participants will receive a pill containing
either DCS or sugar (placebo). Assessment visits will include interviews, self-report
questionnaires, and laboratory tests. These visits will occur at Weeks 1, 7, and 12 during
treatment and at Months 3, 6, and 9 post-treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06274112 -
Using TMS to Understand Neural Processes of Social Motivation
|
N/A | |
Completed |
NCT02554929 -
Treatment of Social Anxiety Disorder and Selective Mutism
|
N/A | |
Completed |
NCT00684541 -
Interpretation Modification Program for Social Phobia
|
N/A | |
Completed |
NCT00684320 -
Attention Disengagement Training for Social Phobia
|
N/A | |
Completed |
NCT03247075 -
Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT
|
N/A | |
Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
Withdrawn |
NCT04622930 -
Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)
|
N/A | |
Active, not recruiting |
NCT05018312 -
Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety
|
N/A | |
Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
Completed |
NCT05858294 -
The Safety, Acceptability and Efficacy of Alena
|
N/A | |
Active, not recruiting |
NCT05600114 -
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Not yet recruiting |
NCT02924610 -
Brief Intervention to Reduce Fear
|
Phase 4 | |
Active, not recruiting |
NCT02592564 -
Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
Unknown status |
NCT01712321 -
Study of Vilazodone to Treat Social Anxiety Disorder
|
N/A | |
Completed |
NCT01320800 -
CBT for Social Anxiety Disorder Delivered by School Counselors
|
Phase 2 | |
Completed |
NCT00485888 -
Flushing in Social Anxiety Disorder on Cipralex
|
Phase 2 | |
Completed |
NCT00485615 -
An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia
|
Phase 2 |